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Abstract
Background: Colorectal cancer (CRC) is one of the leading causes of cancer related morbidity and death. Despite the fact
that the mean age at diagnosis of CRC is lower in men, screening by colonoscopy or fecal occult blood test (FOBT) is
initiated at same age in both genders. The prevalence of the common CRC precursor lesion, advanced adenoma, is well
documented only in the screening population. The purpose of this study was to assess the risk of advanced adenoma at
ages below screening age.
Methods and Findings:We analyzed data from a census of 625,918 outpatient colonoscopies performed in adults in Bavaria
between 2006 and 2008. A logistic regression model to determine gender- and age-specific risk of advanced neoplasia was
developed. Advanced neoplasia was found in 16,740 women (4.6%) and 22,684 men (8.6%). Male sex was associated with an
overall increased risk of advanced neoplasia (odds ratio 1.95; 95% confidence interval, CI, 1.91 to 2.00). At any age and in any
indication group, more colonoscopies were needed in women than in men to detect advanced adenoma or cancer. At age
75 14.8 (95% CI, 14.4–15.2) screening, 18.2 (95% CI, 17.7–18.7) diagnostic, and 7.9 (95% CI, 7.6–8.2) colonoscopies to follow
up on a positive FOBT (FOBT colonoscopies) were needed to find advanced adenoma in women. At age 50 39.0 (95% CI,
38.0–40.0) diagnostic, and 16.3 (95% CI, 15.7–16.9) FOBT colonoscopies were needed. Comparable numbers were reached
20 and 10 years earlier in men than in women, respectively.
Conclusions: At any age and independent of the indication for colonoscopy, men are at higher risk of having advanced
neoplasia diagnosed upon colonoscopy than women. This suggests that starting screening earlier in life in men than in
women might result in a relevant increase in the detection of asymptomatic preneoplastic and neoplastic colonic lesions.
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Introduction
Colorectal cancer is among the leading causes of cancer related
morbidity and mortality in the United States and Europe [1–3].
Screening for colorectal cancer by fecal occult blood testing
(FOBT), flexible sigmoidoscopy, and colonoscopy can detect
precancerous lesions and cancers at early stages [4–6]. However,
colonoscopy is the most sensitive test available and studies have
demonstrated substantial reductions in the expected risk of
colorectal cancer during long-term follow-up after screening
colonoscopy [6–8].
For the average risk population guidelines usually recommend
starting screening at the age of 50 years [9,10]. There are separate
recommendations for individuals at increased risk because of a
family history of colorectal cancer, a genetic predisposition such as
familial adenomatous polyposis coli (FAP) and hereditary nonpol-
yposis colorectal cancer (HNPCC), a personal history of inflamma-
tory bowel disease or prior neoplasia. Recently, the American
College of Gastroenterology has acknowledged the increased risk of
male African Americans [11] and recommends starting screening at
an age of 45 years in this group [12]. Although lifetime risk of
colorectal cancer appears to be similar among men and women, the
age-adjusted rate of advanced adenoma that is detected during
screening is higher in men and colorectal cancer occurs at an earlier
age in men than in women [2,13–18].
Despite these facts it is uncertain whether colorectal cancer
screening should start at an earlier age in men than in women.
Our current knowledge on gender as a risk factor for colorectal
cancer is based on screening populations, high-risk populations,
cancer registry data, and mortality statistics [16,18,19]. Still, we
have limited information on the frequency of advanced adenoma,
the common precursor lesion and main target lesion of colorectal
cancer screening, in the general risk population under the age of
50 years [20]. To provide data on the age- and gender-specific risk
of advanced adenoma, we analyzed population-wide data from a
census of outpatient colonoscopies performed in Bavaria in the
years 2006 through 2008. We determined the age-specific risk of
advanced adenoma and cancer in men and women and developed
logistic regression models to predict the number of colonoscopies
needed to detect advanced adenoma and cancer, i.e. the number
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of persons who have to undergo colonoscopy to detect one lesion,
depending on age and gender.
Methods
Study Design
This study is based on a census of outpatient colonoscopies
obtained as part of routine care in Bavaria, Germany, between
January 2006 and December 2008. The complete documentation
of out-patient colonoscopies is required for reimbursement. No
individual-related data are contained in the data base. Contents
and the procedure of data collection are regulated by the
‘‘Krebsfru¨herkennungs-Richtlinie’’ and have been approved by
the governmental authority for data protection of Bavaria.
More than 83% of the Bavarian population of 12.5 million are
members of sickness funds forming the compulsory health
insurance (CHI) system [21,22]. Reimbursement for outpatient
care of CHI patients requires affiliation of a physician with the
Association of CHI Physicians. Since January 2006 all outpatient
colonoscopies of CHI patients and their histopathological results
are documented electronically in a central database via the
internet. Photographic documentation of the cecal landmarks is
required. A similar federal database covers only screening
colonoscopies, while, uniquely, the Bavarian database documents
all colonoscopies. Only completely documented colonoscopies are
reimbursed. Since October 2002, all CHI insurants aged 55 years
or older are entitled to two screening colonoscopies at an interval
of 10 years. In Bavaria, the cumulative participation rate of CHI
insurants in screening colonoscopy from 2003 through 2008 was
15.1% for women and 13.8% for men, respectively. In the years
2006 through 2008 a total number of 1,955,790 FOBT tests were
reimbursed in Bavaria. In 2008, 13.6% of male and 21.9% of
female CHI insurants between age 50 and 74 received an FOBT.
From January 2006 through December 2008, a total of 802,966
colonoscopies were documented in the database. We excluded
1,997 colonoscopies in patients aged ,18 years and 28,435
examinations of individuals aged $80 years. Additional 107,204
examinations were excluded because they were done for post-
adenoma or post-carcinoma surveillance. After excluding 2,906
doublets and 36,506 records of repeat examinations, a total of
625,918 colonoscopies were included in the analysis. In case of
repeat examinations, the index colonoscopy was included in the
analysis. Biopsy specimens were evaluated by local pathologists
using common criteria. The findings on colonoscopy were
categorized on the basis of the most advanced lesion found.
Advanced adenoma was defined as adenoma that was at least
10 mm in diameter, had high-grade dysplasia, had villous or
tubulovillous histologic characteristics, or any combination thereof
[23]. Advanced neoplasia was defined as cancer or advanced
adenoma.
Table 1. Demographic characteristics for the 625,918 participants aged 18 to 79 years in diagnostic and screening colonoscopy.
Characteristic Screening Colonoscopies FOBT-pos. Colonoscopies Diagnostic Colonoscopies
Men
(N=81,078)
Women
(N=99,826)
Men
(N=16,979)
Women
(N=20.671)
Men
(N=164,661)
Women
(N=242,703)
Age – yr
Range 55–79 55–79 18–79 18–79 18–79 18–79
Mean 6 SD 64.366.3 63.866.4 58.8611.9 58.3612.0 52.1614.4 52.1614.9
Age group – no. (%)
18–39 - - 967 (5.7) 1,324 (6.4) 32,164 (19.5) 49,117 (20.2)
40–44 - - 1,004 (5.9) 1,272 (6.2) 18,478 (11.2) 25,262 (10.4)
45–49 - - 1,889 (11.1) 1,822 (8.8) 21,078 (12.8) 29,081 (12.0)
50–54 - - 2,533 (14.9) 3,634 (17.6) 22,879 (13.9) 32,650 (13.5)
55–59 23,785 (29.3) 32,526 (32.6) 2,033 (12.0) 2,588 (12.5) 15,517 (9.4) 23,784 (9.8)
60–64 18,574 (22.9) 22,537 (22.6) 2,029 (12.0) 2,457 (11.9) 14,024 (8.5) 21,305 (8.8)
65–69 20,862 (25.7) 24,430 (24.5) 2,941 (17.3) 3,438 (16.6) 18,221 (11.1) 27,533 (11.3)
70–74 12,044 (14.9) 13,770 (13.8) 2,208 (13.0) 2,561 (12.4) 13,470 (8.2) 20,506 (8.5)
75–79 5,813 (7.2) 6,563 (6.6) 1,375 (8.1) 1,575 (7.6) 8,830 (5.4) 13,465 (5.6)
Family history – no. (%) 2,774 (3.4) 4,745 (4.8) 550 (3.2) 939 (4.5) 9,908 (6.0) 16,898 (7.0)
Performance characteristics
Intravenous sedation – no. (%) 72,466 (89.4) 95,416 (95.6) 15,409 (90.8) 19,879 (96.2) 152,186 (92.4) 234,587 (96.7)
Cecal intubation – no. (%) 79,803 (98.4) 97,978 (98.2) 16,567 (97.6) 20,138 (97.4) 160,600 (97.5) 235,565 (97.1)
Complications – no. (%)
Bleeding 220 (0.27) 132 (0.13) 81 (0.48) 51 (0.25) 287 (0.17) 239 (0.10)
Perforation 22 (0.03) 24 (0.02) 8 (0.05) 5 (0.02) 23 (0.01) 52 (0.02)
Cardiorespiratory 30 (0.04) 36 (0.04) 9 (0.05) 16 (0.08) 45 (0.03) 65 (0.03)
doi:10.1371/journal.pone.0020076.t001
Figure 1. Predicted probabilities of advanced adenoma (A), cancer (B), and advanced neoplasia (C) in screening and diagnostic
groups according to age and gender. The bands mark the corresponding 95% confidence intervals.
doi:10.1371/journal.pone.0020076.g001
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Statistical Analysis
Data were described using appropriate measures of location and
dispersion. Statistical inferences on the risks of advanced adenoma,
cancer, and advanced neoplasia were based on logistic regression
models including a fixed set of independent variables: Gender,
age, age squared, age cubed (to account for the obvious nonlinear
relations), indication, completeness of the examination, and
intravenous sedation. Intravenous sedation was included because
sedation has previously been shown to be associated with
completeness of colonoscopy [24]. More detailed information is
provided with the supplementary methods S1. While the
presentation of the number of colonoscopies needed to identify
cancer or advanced adenoma and figure 1 were restricted to the
relevant age group of potential screening clients (40 to 79 years of
age), all patients were included in the analyses. We did not use a
data-driven variable selection algorithm. Model fit was assessed
graphically by plotting the observed frequencies and the
probabilities predicted from the regression equations. Following
Regula and co-workers [16], the number of colonoscopies needed
to detect one lesion was defined as the reciprocal of the probability
predicted by the logistic regression model. Analogously, 95%
confidence limits were calculated as reciprocals of the 95%
confidence limits for the predicted probabilities. All analyses were
performed using SAS version 9.2 for Linux (SAS Institute Inc.,
Cary, NC, USA).
Results
A total of 625,918 colonoscopies performed in adults between
18 and 79 years of age were included in the analysis. 407,364
colonoscopies were done for diagnostic reasons, 180,904 were
primary screening colonoscopies performed between 55 and 79
years of age, and 37,650 colonoscopies were screening colonos-
copies performed to follow up on individuals positively pre-
screened by FOBT (FOBT+ colonoscopies). 363,200 participants
were female and 262,718 were male. The characteristics of the
study population are listed in Table 1. Indications for diagnostic
colonoscopies are listed in Table S1. 95% of the diagnostic
colonoscopies, 93.7% of FOBT+ colonoscopies and 92.8% of the
screening colonoscopies were performed with intravenous seda-
tion. In all groups, women more frequently received intravenous
sedation. The cecum was reached in 97.3% of diagnostic, 97.5%
of FOBT+, and 98.3% of screening colonoscopies. Acute
complications were rare, with bleedings occurring overall in
0.16%, perforations in 0.02%, and cardiorespiratory complica-
tions in 0.03% of colonoscopies, respectively.
Colonoscopy findings are presented in Table 2. 55.2% of
screening, 54.9% of FOBT+, and 59.6% of diagnostic colonos-
copies were performed in women. Screening colonoscopy revealed
advanced adenoma in 5,295 women (5.3%) and in 7,923 men
(9.8%) and cancer in 709 (0.7%) women and 1,061 (1.3%) men.
FOBT+ colonoscopies identified advanced adenoma in 1,782
women (8.6%) and 2,522 men (14.9%) and cancer in 524 women
(2.5%) and 746 men (4.4%). Upon diagnostic colonoscopy 6,977
women (2.9%) and 8,821 men (5.4%) were found to carry
advanced adenoma, 1,802 women (0.7%) and 2,340 men (1.4%)
had cancers. Remarkably, the highest rates of advanced adenoma
and cancer were found in FOBT+ colonoscopies in both genders,
reflecting the preselection of this screening group.
A logistic regression model was developed to predict the
probabilities of advanced adenoma, carcinoma, and advanced
neoplasia in all three colonoscopy groups according to gender. We
Table 2. Findings on 625,918 colonoscopies.
Age group - years Gender Screening colonoscopies FOBT+ colonoscopies Diagnostic colonoscopies
Cancer
no. (%*)
Advanced
adenoma
no. (%*)
Cancer
no. (%*)
Advanced
adenoma
no. (%*)
Cancer
no. (%*)
Advanced
adenoma
no. (%*)
18–39 women - - 3 (0.2) 28 (2.1) 73 (0.2) 295 (0.6)
men - - 5 (0.5) 31 (3.2) 67 (0.2) 312 (1.0)
40–44 women - - 11 (0.9) 45 (3.5) 83 (0.3) 383 (1.5)
men - - 17 (1.7) 60 (6.0) 79 (0.4) 488 (2.6)
45–49 women - - 24 (1.3) 113 (6.2) 116 (0.4) 648 (2.2)
men - - 24 (1.3) 177 (9.4) 123 (0.6) 881 (4.2)
50–54 women - - 53 (1.5) 293 (8.1) 184 (0.6) 934 (2.9)
men - - 62 (2.5) 350 (13.8) 207 (0.9) 1,284 (5.6)
55–59 women 114 (0.4) 1,306 (4.0) 58 (2.2) 215 (8.3) 187 (0.8) 758 (3.2)
men 172 (0.7) 1,849 (7.8) 94 (4.6) 294 (14.5) 252 (1.6) 1,070 (6.9)
60–64 women 144 (0.6) 1,107 (4.9) 72 (2.9) 238 (9.7) 184 (0.9) 899 (4.2)
men 173 (0.9) 1,737 (9.4) 93 (4.6) 345 (17.0) 294 (2.1) 1,083 (7.7)
65–69 women 206 (0.8) 1,441 (5.9) 105 (3.1) 344 (10.0) 329 (1.2) 1,231 (4.5)
men 307 (1.5) 2,276 (10.9) 172 (5.9) 548 (18.6) 512 (2.8) 1,595 (8.8)
70–74 women 153 (1.1) 937 (6.8) 115 (4.5) 299 (11.7) 338 (1.7) 1,031 (5.0)
men 255 (2.1) 1,359 (11.3) 153 (6.9) 413 (18.7) 437 (3.2) 1,241 (9.2)
75–79 women 92 (1.4) 504 (7.7) 83 (5.3) 207 (13.1) 308 (2.3) 798 (5.9)
men 154 (2.6) 702 (12.1) 126 (9.2) 304 (22.1) 369 (4.19) 867 (9.8)
*Percentages are given related to the number of individuals in each group according to age, gender, and indication as presented in Table 1.
doi:10.1371/journal.pone.0020076.t002
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found that the probability of finding advanced adenoma, cancer,
or advanced neoplasia is doubled in men at any age in all three
colonoscopy groups (Figure 1A–C). Furthermore, combined
analysis of all colonoscopies revealed odds ratios for men
compared to women for detection of advanced adenoma of 1.92
(95% CI: 1.87–1.96), for detection of cancer of 1.97 (95% CI:
1.88–2.07), and for detection of advanced neoplasia of 1.93 (95%
CI: 1.89–1.97; Table 3, Table S2, and Figure S1).
Advanced neoplasia includes advanced adenoma and cancer
and has been suggested as the most appropriate target for
colorectal cancer screening [4,14,16,18,23,25–27]. To determine
whether screening for advanced neoplasia should start earlier in
men than in women prevalence data of advanced adenoma from
age groups below the current start age of screening are required.
Our analysis reveals that the number of colonoscopies needed to
detect cancer or advanced adenoma is higher in women than in
men at all ages and in all three colonoscopy indications analyzed
(Table 4). At age 75 a total of 14.8 (95% CI, 14.4–15.2) screening,
18.2 (95% CI, 17.7–18.7) diagnostic, or 7.9 (95% CI, 7.6–8.2)
FOBT+ colonoscopies were needed to find advanced adenoma in
women. Comparable numbers were reached up to twenty years
earlier in men. At age 50, the age screening is usually initiated,
39.0 (95% CI, 38.0–40.0) diagnostic, and 16.3 (95% CI, 15.7–
16.9) FOBT+ colonoscopies were required to find advanced
adenoma in women. Similar numbers were reached in men
between age 40 to 41 with 41.5 (95% CI, 40.0–43.0) to 38.1 (95%
CI, 36.8–39.4) diagnostic colonoscopies, and 17.2 (16.5–18.1) to
15.9 (15.2–16.6) FOBT+ colonoscopies, respectively.
Discussion
The lifetime risk of colorectal cancer is similar in women and in
men [28], but screening studies including individuals 50 years of
age and above have demonstrated that advanced adenoma and
cancer occur at an earlier age in men [14,17,18]. Still, more
detailed information on the risk of advanced colonic neoplasia in
women and men below the age of 50 is needed for the
implementation of modifications of screening guidelines concern-
ing the age of onset of screening dependent on gender [20]. In our
study of 625,918 persons who received colonoscopies in Bavaria
between 2006 and 2008, the large number of participants allowed
us to derive a reliable statistical model to predict the age-
dependent risks of women and men for advanced adenoma and
cancer. We found that throughout all age groups the risk of
advanced neoplasia was higher in men than in women and nearly
twice as many cases of advanced colorectal neoplasia were
detected in men than in women of same age.
Since colorectal cancer rates begin to increase in the sixth
decade of life in average-risk individuals, an age of 50 years has
been arbitrarily selected as an appropriate age to initiate
colonoscopy screening for both genders [9,10,12]. However,
age-adjusted incidence and mortality rates of colorectal cancer
are higher in men than in women who reach the levels observed in
men 4 to 10 years later [19]. Similarly, screening studies have
demonstrated that during their sixth decade women have lower
absolute risks of advanced neoplasia than men [16,18]. We
demonstrate that men reach the same risk of advanced neoplasia
10 and more years earlier than women. Our data are in line with
findings of screening studies [20] but by including diagnostic and
FOBT+ colonoscopies allow for the first time more precise risk
estimations for neoplastic and preneoplastic lesions in women and
men before the age of 50 in a general risk population. Moreover,
in contrast to screening studies, which only include samples of
volunteers [4,14,16,18,23,25,26,29] our data are based on a near-
complete census of all outpatient colonoscopies in the Bavarian
population. These data allow estimating the risk of the general
population below the age of 50 while previous studies have only
included few individuals of this age group [29] or included
younger individuals at increased risk only [16]. As demonstrated
by our analysis, also non-screening colonoscopies performed in a
given population can be used to identify the age at which men and
women reach comparable risks. The age differences in numbers of
colonoscopies needed to detect advanced lesions are similar in all
three colonoscopy groups analyzed. In case of a negative screening
colonoscopy re-colonoscopy is commonly recommended after 10
years [9,10]. Due to the low risk of colorectal cancer and advanced
adenomas 10 and more years after negative colonoscopy an
extension of this interval has been suggested [7]. Yet, it remains to
be studied, whether gender-dependent differences of risk need to
Table 3. Predictors of advanced adenoma, carcinoma, and
advanced neoplasia.
Parameter
Odds Ratio
(OR)
95% CI of
the OR P
Advanced Adenoma
Male gender 1.915 1.872–1.959 ,.0001
Age (per year) 1.387 1.316–1.463 ,.0001
Age2 (per year) 0.996 0.995–0.997 ,.0001
Age3 (per year) 1.000 1.000–1.000 ,.0001
FOBT+ vs. diagnostic
colonoscopy
2.492 2.403–2.584 ,.0001
Screening vs. diagnostic
colonoscopy
1.246 1.215–1.278 ,.0001
Colonoscopy complete vs.
incomplete
1.201 1.112–1.296 ,.0001
Sedation (yes vs. no) 0.991 0.948–1.036 0.7019
Cancer
Male gender 1.971 1.878–2.068 ,.0001
Age (per year) 0.977 0.897–1.064 0.5896
Age2 (per year) 1.002 1.000–1.003 0.0175
Age3 (per year) 1.000 1.000–1.000 0.0055
FOBT+ vs. diagnostic
colonoscopy
2.701 2.529–2.885 ,.0001
Screening vs. diagnostic
colonoscopy
0.642 0.605–0.681 ,.0001
Colonoscopy complete vs.
incomplete
0.105 0.099–0.112 ,.0001
Sedation (yes vs. no) 1.201 1.089–1.324 0.0002
Advanced Neoplasia
Male gender 1.933 1.893–1.974 ,.0001
Age (per year) 1.297 1.238–1.358 ,.0001
Age2 (per year) 0.997 0.996–0.998 ,.0001
Age3 (per year) 1.000 1.000–1.000 ,.0001
FOBT+ vs. diagnostic
colonoscopy
2.614 2.529–2.702 ,.0001
Screening vs. diagnostic
colonoscopy
1.133 1.107–1.161 ,.0001
Colonoscopy complete vs.
incomplete
0.443 0.421–0.465 ,.0001
Sedation (yes vs. no) 1.026 0.984–1.069 0.2324
doi:10.1371/journal.pone.0020076.t003
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be taken into account when discussing the extension of screening
intervals.
The performance rate as determined by the cecum rate was
high in our setting and comparable to other reports or higher and
within the range expected for expert colonoscopists [16,23,30].
The data presented here document that colonoscopy is safe in both
the screening and diagnostic settings. The rate of advanced
neoplasia found in the screening and diagnostic settings is within
the range of other studies reporting frequencies of advanced
neoplasia between 5.6 and 10.6% for both genders
[4,14,16,18,25]. The higher prevalence of cancer in the diagnostic
and FOBT+ groups is explained by the fact that these
colonoscopies were performed because of complaints or occult
blood in stool. In contrast, the higher prevalence of advanced
adenoma in both screening populations suggests that people at
higher risk of colorectal cancer including those with a specific
family history might more frequently accept the offer of screening
[13]. Moreover, the higher probability of asymptomatic individ-
uals to be diagnosed with advanced adenoma or advanced
neoplasia upon colonoscopy than symptomatic individuals might
also be influenced by the fact that symptomatic individuals receive
colonoscopies more frequently in a hospital setting. The decline in
the number of diagnostic colonoscopies at the age of 55 when
screening colonoscopy is offered might indicate that a certain
number of diagnostic colonoscopies before the age of 55 may have
been performed for subtle symptoms or for screening but were not
documented as screening colonoscopies before the age of 55.
Similar to previous reports, we also observed that women
outnumber men in screening colonoscopies [16]. Interestingly, this
also holds true for the other colonoscopy indications suggesting a
greater health consciousness of women [26]. It has been discussed
that more men than women receive a screening colonoscopy for
subtle symptoms potentially related to colorectal cancer and that
this selection bias might be the reason for the higher prevalence of
advanced neoplasia in men [16]. However, our data demonstrate
that male gender is associated with a higher probability of
advanced neoplasia independent of the indication for colonoscopy.
Sex-related biologic differences like hormonal effects before
menopause and hormone-replacement therapy may in addition
to different life styles exert a protective effect and explain the
reduced risk for colorectal cancer in women [31]. Still,
participation in screening colonoscopy in Bavaria remains low in
both women and men. However, the participation rate in other
population-level colorectal cancer screening programs throughout
the world is currently unknown [1]. Similar as in the case of
screening colonoscopy, women also more frequently accept the
Table 4. Number of colonoscopies needed to identify cancer or advanced adenoma.
Indication
Age
(yrs) Cancer
Advanced
adenoma
Male
n (95% CI)
Female
n (95% CI)
Male
n (95% CI)
Female
n (95% CI)
Screening
Colonoscopies
75 51.8 (48.7–55.0) 101.0 (94.6–107.9) 8.2 (8.0–8.4) 14.8 (14.4–15.2)
70 63.8 (60.6–67.3) 124.9 (117.9–132.3) 9.0 (8.8–9.1) 16.2 (15.9–16.6)
65 82.4 (78.2–87.0) 161.5 (152.4–171.2) 9.9 (9.7–10.1) 18.1 (17.7–18.5)
60 110.2 (104.3–116.5) 216.3 (203.8–229.6) 11.3 (11.1–11.6) 20.8 (20.3–21.2)
55 151.2 (142.2–160.7) 297.0 (278.2–317.0) 13.5 (13.2–13.8) 24.9 (24.2–25.5)
FOBT
+ Colonoscopies
75 13.1 (12.3–13.9) 24.8 (23.1–26.6) 4.6 (4.5–4.7) 7.9 (7.6–8.2)
70 15.9 (15.0–16.9) 30.5 (28.5–32.5) 5.0 (4.8–5.1) 8.6 (8.3–8.9)
65 20.4 (19.1–21.7) 39.2 (36.6–419) 5.5 (5.3–5.6) 9.5 (9.2–9.9)
60 27.0 (25.3–28.7) 52.2 (48.8–55.8) 6.2 (6.0–6.3) 10.9 (10.5–11.3)
55 36.7 (34.3–39.2) 71.4 (66.5–76.6) 7.2 (7.0–7.5) 12.9 (12.5–13.4)
50 50.8 (47.1–54.7) 99.1 (91.7–107.2) 9.0 (8.7–9.3) 16.3 (15.7–16.9)
45 70.8 (65.0–77.1) 138.6 (126.8–151.4) 11.9 (11.5–12.4) 21.9 (21.0–22.8)
40 98.3 (89.2–108.4) 192.8 (174.4–213.1) 17.2 (16.5–18.1) 32.1 (30.6–33.7)
Diagnostic
Colonoscopies
75 33.6 (31.9–35.3) 65.2 (61.8–68.8) 10.0 (9.7–10.2) 18.2 (17.7–18.7)
70 41.4 (39.5–43.3) 80.5 (76.7–84.6) 10.9 (10.7–11.2) 20.0 (19.5–20.4)
65 53.3 (50.8–55.9) 104.0 (98.9–109.4) 12.1 (11.8–12.4) 22.3 (21.8–22.8)
60 71.1 (67.9–74.5) 139.2 (132.5–146.3) 13.9 (13.6–14.2) 25.6 (25.0–26.2)
55 97.4 (92.8–102.3) 191.0 (181.4–201.1) 16.5 (16.2–16.9) 30.7 (30.0–31.5)
50 135.5 (128.0–143.4) 266.1 (250.7–282.4) 20.8 (20.3–21.4) 39.0 (38.0–40.0)
45 189.5 (177.0–202.1) 372.5 (347.1–399.7) 28.2 (27.4–29.0) 53.1 (51.5–54.7)
40 263.8 (243.2–286.1) 518.9 (477.6–563.8) 41.5 (40.0–43.0) 78.5 (75.6–81.5)
doi:10.1371/journal.pone.0020076.t004
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offer for FOBT screening in Bavaria. Our data confirm the well-
known fact that pre-screening by FOBT results in a lower number
of colonoscopies needed to identify cancer or advanced adenoma.
However, its overall sensitivity for advanced colonic lesions is very
limited compared to colonoscopy [4,5,32].
We demonstrate that levels of incidence of advanced neoplasia
differ strongly between both genders depending on age. This
suggests that women do not benefit from a start of screening at age
50 or 55 years to the same extent as men. Currently, either women
might be subjected to screening unnecessarily early in life or start
of screening might be delayed in men. It has been suggested that
compliance with screening recommendations may improve if
individuals understand that recommendations for screening are
based on their personal risk, rather than the selection of an
arbitrary age [33]. The increased risk of family history has been
widely acknowledged by screening guidelines [9,10,12]. However,
a gender-specific recommendation of age for start of screening for
colorectal cancer might even be more relevant from a public
health point of view than the differentiation by family history [13].
The American College of Gastroenterology suggests starting
screening in male African Americans at age 45 in contrast to
women and white men [12]. Yet, the evidence for this
recommendation is mainly based on cancer epidemiology data
[11]. Next to gender, family history, and race, other factors such as
smoking status, alcohol consumption, obesity, and diabetes
mellitus [32] might also be taken into account in the future to
define the individual risk. Still, it needs to be kept in mind that
more complicated recommendations and the choice between
various screening modalities might also result in confusion and
non-compliance with screening guidelines [34].
A limitation of this study is that family history was documented
less detailed than in some screening studies [16]. Since our data
picture the common practice in everyday outpatient care, and
taking detailed family histories may not regularly be part of this
routine, our data may give a valid impression of the population
mix of individuals at general risk and persons from family risk
populations. Moreover, assuming a similar distribution of family
risk between men and women, inclusion of family history in our
model would not result in a major change in the gender-dependent
differences reported. Three factors may have influenced the
number of advanced neoplasia included in the analysis: Colonos-
copies done in privately insured patients and colonoscopies
performed in hospitals are not documented in the data base. As
the majority of the inhabitants of Bavaria are members of the CHI
system and colonoscopies performed in hospitals are generally
done in more severely ill patients, this might be a negligible bias or,
at best, result in an underestimate of advanced neoplasia. Only
complete documentations on size and histology resulted in
inclusion of lesions into the analysis, this also might have resulted
in an underestimate. Similar as in other large studies [16] no
central pathological review of lesions has been performed and it is
unknown whether the potential misclassification of lesions has a
relevant impact on our database. However, a potential bias due to
these three factors would most likely only affect the total number
of lesions but not the relative distribution of lesions between men
and women and, therefore, not affect the gender-dependent
differences either.
In summary, male gender is a risk factor for finding advanced
adenoma or cancer upon colonoscopy independent of the
indication for colonoscopy. At any age between 40 and 79 years,
men are at higher risk of having advanced neoplasia diagnosed
upon colonoscopy than women. This suggests that starting
screening earlier in life in men than in women might result in a
relevant increase in the detection of asymptomatic preneoplastic
and neoplastic colonic lesions.
Supporting Information
Methods S1
(PDF)
Table S1 Indications for diagnostic colonoscopies.
(PDF)
Table S2 Regression coefficients.
(PDF)
Figure S1 Relative risk (RR) of advanced neoplasia in
men compared to women depending on age. The black
line shows the observed, unadjusted RR at each year of age. The
band marks the corresponding 95% confidence intervals.
(PDF)
Acknowledgments
The support by the LMUinnovativ project Munich Center of Health
Sciences, subproject II (evidence-based prevention and modeling of
chronic diseases) is gratefully acknowledged.
Author Contributions
Conceived and designed the experiments: FTK AC AM AW UM BG.
Analyzed the data: FTK AC AW UM BG. Contributed reagents/
materials/analysis tools: AM. Wrote the paper: FTK AC UM.
References
1. Gellad ZF, Weiss DG, Ahnen DJ, Lieberman DA, Jackson GL, et al. (2010)
Colonoscopy withdrawal time and risk of neoplasia at 5 years: results from VA
Cooperative Studies Program 380. Am J Gastroenterol 105: 1746–1752.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009.
CA Cancer J Clin 59: 225–249.
3. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA
Cancer J Clin 55: 74–108.
4. Lieberman DA, Weiss DG (2001) One-time screening for colorectal cancer with
combined fecal occult-blood testing and examination of the distal colon.
N Engl J Med 345: 555–560.
5. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, et al. (1993)
Reducing mortality from colorectal cancer by screening for fecal occult blood.
Minnesota Colon Cancer Control Study. N Engl J Med 328: 1365–1371.
6. Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, et al. (1993)
Prevention of colorectal cancer by colonoscopic polypectomy. The National
Polyp Study Workgroup. N Engl J Med 329: 1977–1981.
7. Brenner H, Haug U, Arndt V, Stegmaier C, Altenhofen L, et al. (2010) Low risk
of colorectal cancer and advanced adenomas more than 10 years after negative
colonoscopy. Gastroenterology 138: 870–876.
8. Muller AD, Sonnenberg A (1995) Prevention of colorectal cancer by flexible
endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann
Intern Med 123: 904–910.
9. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, et al. (2008)
Screening and surveillance for the early detection of colorectal cancer and
adenomatous polyps, 2008: a joint guideline from the American Cancer Society,
the US Multi-Society Task Force on Colorectal Cancer, and the American
College of Radiology. Gastroenterology 134: 1570–1595.
10. Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, et al.
(2008) [Update S3-guideline ‘‘colorectal cancer’’ 2008]. ZGastroenterol 46: 799–840.
11. Agrawal S, Bhupinderjit A, Bhutani MS, Boardman L, Nguyen C, et al. (2005)
Colorectal cancer in African Americans. Am J Gastroenterol 100: 515–23;
discussion 514.
12. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, et al. (2009)
American College of Gastroenterology guidelines for colorectal cancer screening
2009 [corrected]. Am J Gastroenterol 104: 739–750.
13. Brenner H, Hoffmeister M, Stegmaier C, Brenner G, Altenhofen L, et al. (2007)
Risk of progression of advanced adenomas to colorectal cancer by age and sex:
estimates based on 840,149 screening colonoscopies. Gut 56: 1585–1589.
Gender and Risk of Advanced Neoplasia
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e20076
14. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, et al. (2000) Risk of
advanced proximal neoplasms in asymptomatic adults according to the distal
colorectal findings. N Engl J Med 343: 169–174.
15. Mansmann U, Crispin A, Henschel V, Adrion C, Augustin V, et al. (2008)
Epidemiology and quality control of 245 000 outpatient colonoscopies. Dtsch
Arztebl Int 105: 434–440.
16. Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, et al. (2006)
Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia.
N Engl J Med 355: 1863–1872.
17. Rex DK, Lehman GA, Ulbright TM, Smith JJ, Pound DC, et al. (1993) Colonic
neoplasia in asymptomatic persons with negative fecal occult blood tests:
influence of age, gender, and family history. Am J Gastroenterol 88: 825–831.
18. Schoenfeld P, Cash B, Flood A, Dobhan R, Eastone J, et al. (2005) Colonoscopic
screening of average-risk women for colorectal neoplasia. N Engl J Med 352:
2061–2068.
19. Brenner H, Hoffmeister M, Arndt V, Haug U (2007) Gender differences in
colorectal cancer: implications for age at initiation of screening. Br J Cancer 96:
828–831.
20. Nguyen SP, Bent S, Chen YH, Terdiman JP (2009) Gender as a risk factor for
advanced neoplasia and colorectal cancer: a systematic review and meta-
analysis. Clin Gastroenterol Hepatol 7: 676–81.e1–3.
21. Website of the GermanMinistry of Health. Available: http://www.bmg.bund.de/
cln_160/nn_1168248/SharedDocs/Downloads/DE/Statistiken/Gesetzliche
Krankenversicherung/Mitglieder-und-Versicherte/2007-km6-pdf,templateId=raw,
property=publicationFile.pdf/2007-km6-pdf.pdf. Accessed 2010 May 17.
22. Website of the Statistical Offices of the Federation and the La¨nder. Available:
http://www.statistik-portal.de/Statistik-Portal/de_jb01_jahrtab1.asp. Accessed
2010 May 17.
23. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, et al. (2000) Use of
colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans
Affairs Cooperative Study Group 380. N Engl J Med 343: 162–168.
24. Crispin A, Birkner B, Munte A, Nusko G, Mansmann U (2009) Process quality
and incidence of acute complications in a series of more than 230,000 outpatient
colonoscopies. Endoscopy 41: 1018–1025.
25. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, et al. (2003) Using
risk for advanced proximal colonic neoplasia to tailor endoscopic screening for
colorectal cancer. Ann Intern Med 139: 959–965.
26. Strul H, Kariv R, Leshno M, Halak A, Jakubowicz M, et al. (2006) The
prevalence rate and anatomic location of colorectal adenoma and cancer
detected by colonoscopy in average-risk individuals aged 40–80 years.
Am J Gastroenterol 101: 255–262.
27. Winawer SJ, Zauber AG (2002) The advanced adenoma as the primary target of
screening. Gastrointest Endosc Clin N Am 12: 1–9, v.
28. Website of the American Cancer Society. Available: http://www.cancer.org/
downloads/STT/CAFF2007PWSecured.pdf. Accessed 2010 May 17.
29. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, et al. (2002) Results
of screening colonoscopy among persons 40 to 49 years of age. N Engl J Med
346: 1781–1785.
30. Rex DK, Bond JH, Winawer S, Levin TR, Burt RW, et al. (2002) Quality in the
technical performance of colonoscopy and the continuous quality improvement
process for colonoscopy: recommendations of the U.S. Multi-Society Task Force
on Colorectal Cancer. Am J Gastroenterol 97: 1296–1308.
31. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al.
(2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal
women: principal results From the Women’s Health Initiative randomized
controlled trial. JAMA 288: 321–333.
32. Kahi CJ, Rex DK, Imperiale TF (2008) Screening, surveillance, and primary
prevention for colorectal cancer: a review of the recent literature. Gastroenter-
ology 135: 380–399.
33. Lieberman D (2005) Race, gender, and colorectal cancer screening.
Am J Gastroenterol 100: 2756–2758.
34. Jones RM, Vernon SW, Woolf SH (2010) Is discussion of colorectal cancer
screening options associated with heightened patient confusion? Cancer
Epidemiol Biomarkers Prev 19: 2821–2825.
Gender and Risk of Advanced Neoplasia
PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e20076
